Compare NAN & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAN | ALDX |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 356.7M | 317.7M |
| IPO Year | N/A | 2014 |
| Metric | NAN | ALDX |
|---|---|---|
| Price | $11.39 | $4.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 79.7K | ★ 1.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $123.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.69 | $1.18 |
| 52 Week High | $11.67 | $6.99 |
| Indicator | NAN | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 40.45 | 34.77 |
| Support Level | $11.37 | $2.60 |
| Resistance Level | $11.50 | $5.70 |
| Average True Range (ATR) | 0.08 | 0.43 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 17.19 | 6.36 |
Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.